<div id="readability-page-1"><p>Core Laboratories (NYSE:CLB - Get Free Report) released its quarterly earnings data on Wednesday. The oil and gas company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.19 by $0.03, Zacks reports. Core Laboratories had a net margin of 5.73% and a return on equity of 14.15%. The business had revenue of $134.52 million during the quarter, compared to analyst estimates of $130.92 million. During the same quarter last year, the business earned $0.25 earnings per share. Core Laboratories's quarterly revenue was up .1% compared to the same quarter last year.  Core Laboratories updated its Q4 2025 guidance to 0.180-0.22 EPS.</p><div><p><span></span><span>Get <strong>Core Laboratories</strong> alerts:</span></p></div><h2>Core Laboratories Price Performance</h2><p>Core Laboratories stock opened at $12.81 on Thursday. Core Laboratories has a 12-month low of $9.72 and a 12-month high of $21.83. The firm has a 50-day moving average price of $11.81 and a 200-day moving average price of $11.74. The firm has a market capitalization of $600.66 million, a PE ratio of 20.66, a price-to-earnings-growth ratio of 6.66 and a beta of 1.38. The company has a current ratio of 2.27, a quick ratio of 1.70 and a debt-to-equity ratio of 0.47. </p><h2>Core Laboratories Announces Dividend</h2><p>The company also recently announced a quarterly dividend, which will be paid on Monday, November 24th. Stockholders of record on Monday, November 3rd will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, November 3rd. Core Laboratories's dividend payout ratio (DPR) is 6.45%. </p><h2>Institutional Investors Weigh In On Core Laboratories</h2><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its holdings in  Core Laboratories by 37.6% during the 2nd quarter. Bank of America Corp DE now owns 231,813 shares of the oil and gas company's stock valued at $2,670,000 after buying an additional 63,381 shares in the last quarter.  Raymond James Financial Inc. lifted its holdings in  Core Laboratories by 14.2% during the 2nd quarter. Raymond James Financial Inc. now owns 221,465 shares of the oil and gas company's stock valued at $2,551,000 after buying an additional 27,563 shares in the last quarter.  Ameriprise Financial Inc. lifted its holdings in  Core Laboratories by 7.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 194,410 shares of the oil and gas company's stock valued at $2,240,000 after buying an additional 13,522 shares in the last quarter.  Public Sector Pension Investment Board lifted its holdings in  Core Laboratories by 7.4% during the 2nd quarter. Public Sector Pension Investment Board now owns 159,437 shares of the oil and gas company's stock valued at $1,837,000 after buying an additional 10,961 shares in the last quarter.  Finally, American Century Companies Inc. increased its position in  Core Laboratories by 14.3% during the 2nd quarter. American Century Companies Inc. now owns 133,033 shares of the oil and gas company's stock valued at $1,533,000 after purchasing an additional 16,677 shares during the period. Institutional investors own  97.81% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>Several equities analysts have commented on the stock. Weiss Ratings  reiterated a &#34;sell (d+)&#34; rating on shares of Core Laboratories in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Core Laboratories from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, July 26th. Stifel Nicolaus lowered their target price on shares of Core Laboratories from $13.00 to $12.00 and set a &#34;hold&#34; rating for the company in a report on Wednesday, July 16th. Finally, Zacks Research upgraded shares of Core Laboratories from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Friday, August 15th. Three research analysts have rated the stock with a Hold rating and one  has issued  a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Reduce&#34; and a consensus price target of $12.50.</p><p><b>View Our Latest Stock Report on CLB</b></p><h2>About Core Laboratories</h2> (Get Free Report)<p>Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Core Laboratories</li><li>How to Use High Beta Stocks to Maximize Your Investing Profits</li><li>Quanta Services: The Backbone of the AI Data Center Push</li><li>How to Calculate Stock Profit </li><li>Archer’s Recent String of Victories Signals a New Phase of Growth</li><li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li><li>3 Key Stocks Boosting Buybacks Amid Improving Fundamentals</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNMQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNMQg"/></p><h2>Should You Invest $1,000 in Core Laboratories Right Now?</h2><p>Before you consider Core Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Core Laboratories wasn't on the list.</p><p>While Core Laboratories currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Core Laboratories (NYSE:CLB) reported quarterly earnings of $0.22 per share, exceeding estimates of $0.18. The company had a net margin of 5.73% and a return on equity of 14.15%, with revenues of $134.52 million. Core Laboratories also announced a quarterly dividend of $0.01, payable on November 24. Institutional investors hold 97.81% of the stock, and analysts have mixed ratings, with a consensus price target of $12.50. The stock opened at $12.81, with a 12-month range of $9.72 to $21.83.</p>

Core Laboratories (NYSE:CLB) Announces Quarterly Earnings Results